Newron Pharmaceuticals SpA (FRA:NP5) Common Stock: €4.00 Mil (As of Dec. 2025)


FRA:NP5 Newron Pharmaceuticals SpA FRA:NP5
64 GF Score
Price €13.15
GF Value €14.78
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Common Stock?

Newron Pharmaceuticals SpA FRA:NP5 -5.40% 64 Common Stock is €4.00 Mil as of Dec. 2025. GuruFocus rates FRA:NP5 with a GF Score™ of 64/100 and a GF Value™ of €14.78 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Newron Pharmaceuticals SpA's quarterly common stock stayed the same from Dec. 2024 (€3.99 Mil) to Jun. 2025 (€3.99 Mil) but then increased from Jun. 2025 (€3.99 Mil) to Dec. 2025 (€4.00 Mil).

Newron Pharmaceuticals SpA's annual common stock increased from Dec. 2023 (€3.57 Mil) to Dec. 2024 (€3.99 Mil) and increased from Dec. 2024 (€3.99 Mil) to Dec. 2025 (€4.00 Mil).

Newron Pharmaceuticals SpA Common Stock Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA Common Stock Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.57 3.57 3.57 3.99 4.00

Newron Pharmaceuticals SpA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.57 3.81 3.99 3.99 4.00
FRA:NP5
64GF Score
Newron Pharmaceuticals SpA FRA:NP5
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newron Pharmaceuticals SpA Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €4.00 Mil mean?
Newron Pharmaceuticals SpA (FRA:NP5) has a Common Stock of €4.00 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Newron Pharmaceuticals SpA and its competitors.
Is Newron Pharmaceuticals SpA's Common Stock too high?
Newron Pharmaceuticals SpA's current Common Stock is €4.00 Mil. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Common Stock compare to VRTX and REGN?
Newron Pharmaceuticals SpA's Common Stock of €4.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Newron Pharmaceuticals SpA and its competitors. Newron Pharmaceuticals SpA's current Common Stock is €4.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (FRA:NP5) is currently considered Modestly Undervalued. The stock's GF Value™ is €14.78, compared to a current price of €13.15 — trading 11% below its estimated fair value. The current Common Stock is €4.00 Mil. Newron Pharmaceuticals SpA's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (FRA:NP5), the current Common Stock is €4.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (FRA:NP5) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of €13.15 is trading 11% below its estimated GF Value™ of €14.78. GuruFocus considers Newron Pharmaceuticals SpA to be Modestly Undervalued.

Key valuation signals for FRA:NP5:

  • Common Stock: €4.00 Mil
  • GF Value™: €14.78 vs. price of €13.15 (11% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the FRA:NP5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
64GF Score

Get the complete analysis for FRA:NP5

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.15
Price
€14.78
GF Value